dTAG 和 aTAG 降解剂

The different TAG Degradation platforms all require the protein of interest to be expressed as a fusion with a TAG protein (also known as a degron tag) via transgene expression or CRISPR-mediated locus-specific knock-in (see resources section below for protocols). Subsequent treatment with the relevant TAG Degrader targets the entire fusion protein for degradation. Heterobifunctional TAG Degraders mediate the formation of a ternary complex between an E3 ubiquitin ligase, such as cereblon (CRBN) or von Hippel Lindau (VHL) protein, and the fusion protein. This leads to polyubiquitination of the target protein and the subsequent degradation of the entire fusion protein by the proteasome. dTAG, aTAG and BromoTag Degraders act catalytically, repeatedly engaging and directing the ubiquitination of target molecules. They are cell-permeable and are suitable for in vitro and in vivo applications. The key difference between the dTAG, aTAG and BromoTag technologies is the identity of the TAG protein used.